The use of combination therapy with a biologic agent and immunosuppressant has well-
established efficacy and safety and is common practice in the management of inflammatory …

Inflammatory bowel disease (IBD) is entering a potentially new era of combined
therapeutics. Triantafillidis et al provide an insightful review of the current state of …

Current therapies used in the treatment of inflammatory bowel disease (IBD) are not effective
in all patients. Biologic agents result in approximately 40% remission rates at 1 year in …

Background and Aims We conducted a systematic review and meta-analysis to summarize
emerging data on the safety and effectiveness of dual biologic therapy in combination or …

Biologicals and small molecules have revolutionized the medical management of
inflammatory bowel diseases (IBD), yet they are only effective in a proportion of patients, and …

Abstract Background and Objective Inflammatory Bowel Diseases (IBD) are chronic
nonspecific intestinal inflammatory diseases with a relapsing-remitting course, including …

Inflammatory bowel disease (IBD) is a group of chronic diseases that includes ulcerative
colitis, Crohn's disease, and indeterminate colitis. Patients with IBD require prolonged …

Objective There are limited data on using more than one biologic or small molecule drug
combined to treat patients with inflammatory bowel disease. The aim of our study was to …

Abstract Treatment strategies for inflammatory bowel disease (IBD) are rapidly evolving with
the development of biologics and small molecule drugs (SMDs). However, these drugs are …

The expanding therapeutic armamentarium available for inflammatory bowel disease (IBD)
as well as multiple compounds in clinical development inevitably raises questions as to their …